Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. This is primarily caused by resisting leukemic stem cells (LSCs), which preven...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leukemia
Autori principali: Parting, Oliver, Langer, Samantha, Kuepper, Maja Kim, Wessling, Caroline, Li, Shaoguang, Braunschweig, Till, Chatain, Nicolas, Maié, Tiago, Costa, Ivan G., Crysandt, Martina, Huber, Michael, Brümmendorf, Tim H., Koschmieder, Steffen, Schemionek, Mirle
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515845/
https://ncbi.nlm.nih.gov/pubmed/32684632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0977-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi